Statistical analysis
tumor
TUMOR
All patients who received at least one dose of GC1118 are eligible for safety analysis. For efficacy analysis, patients who were treated by at least one dose of GC1118 and had available tumor assessment were included.The primary endpoint was PFS6. We applied the binomial test to compare the PFS6 of this study to previous results from the available relevant literatures (10% [range: 11%–20%]).All statistical analyses were performed using R version 3.6.3 (